Effects of pituitary adenylate cyclase-activating polypeptide on hormone secretion by human pituitary adenomas in vitro.

Abstract

Hormone release in culture in response to pituitary adenylate cyclase-activating polypeptide (PACAP) was examined in 28 human pituitary adenomas: 10 null cell adenomas, 4 gonadotropin-, 6 GH-, 6 ACTH-, and 2 PRL-producing adenomas. The effects of PACAP38 were compared with those of the classical hypothalamic releasing hormones and other activators of intracellular signaling pathways. PACAP38 significantly stimulated GH release from 1 somatotrope tumor (125 +/- 3% of control; P < 0.05) and ACTH release from 3 corticotrope tumors (134 +/- 6%, 136 +/- 7%, and 137 +/- 9% of control; P < 0.05). The effects of PACAP38 were less potent than either GHRH on GH release in the somatotrope tumor or CRH on ACTH release in the corticotrope tumors but similar to the responses seen with the cAMP analog 8-bromo-cAMP (8-Br-cAMP). No detectable effects of PACAP38 on hormone release from null cell, gonadotropin-, or PRL-producing adenomas were observed. Of the 5 somatotrope tumors that failed to respond to PACAP38, all also failed to respond to either 8-Br-cAMP, TRH, or GHRH. Of the corticotrope tumors that failed to respond, 2 of the 3 also failed to respond to CRH. In addition to eliciting hormone release appropriate to the tumor type, PACAP38 also stimulated glycoprotein hormone alpha-subunit (alpha SU) release from one somatotrope tumor (229 +/- 35% of control, P < 0.01) and one corticotrope tumor (149 +/- 4% of control; P < 0.01). This response was not mimicked by 8-Br-cAMP in the somatotrope tumor, but in the corticotrope tumor a significant alpha SU release was also seen after stimulation with the protein kinase C activator 12-O-tetradecanoyl-phorbol-13-acetate and 8-Br-cAMP. These results suggest that the novel hypothalamic peptide PACAP38 has a modest role in the regulation of GH, ACTH, and alpha SU secretion from some human tumourous pituitary corticotropes and somatotropes. Further studies are needed to elucidate the intracellular signaling pathways that mediate the effects of PACAP on hormone secretion by these tumor types.

• Authors: B J Desai, J P Monson, J G Holdstock, S J Aylwin, J F Geddes, D F Wood, J M Burrin
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 79 Issue 6 Pg. 1771-7 (Dec 1994) ISSN: 0021-972X [Print] United States
• PMID: 7527412 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ADCYAP1 protein, human
• Glycoprotein Hormones, alpha Subunit
• Neuropeptides
• Neurotransmitter Agents
• Pituitary Adenylate Cyclase-Activating Polypeptide
• 8-Bromo Cyclic Adenosine Monophosphate
• Adrenocorticotropic Hormone
• Prolactin
• Growth Hormone
• Corticotropin-Releasing Hormone
• Growth Hormone-Releasing Hormone
• Tetradecanoylphorbol Acetate

Topics

• 8-Bromo Cyclic Adenosine Monophosphate (pharmacology)
• Adenoma (metabolism)
• Adrenocorticotropic Hormone (metabolism)
• Corticotropin-Releasing Hormone (pharmacology)
• Glycoprotein Hormones, alpha Subunit (metabolism)
• Growth Hormone (metabolism)
• Growth Hormone-Releasing Hormone (pharmacology)
• Humans
• Neuropeptides (pharmacology)
• Neurotransmitter Agents (pharmacology)
• Pituitary Adenylate Cyclase-Activating Polypeptide
• Pituitary Neoplasms (metabolism)
• Prolactin (metabolism)
• Tetradecanoylphorbol Acetate (pharmacology)
• Tumor Cells, Cultured